Universität zu Köln

Guellrich, C., Noessner, E., Pfister, D. and Gruenwald, V (2020). Targeted molecular therapy and immunotherapy for prostate cancer. Urologe, 59 (6). S. 687 - 695. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563

Full text not available from this repository.

Abstract

For decades, the treatment of advanced prostate cancer was mainly based on the manipulation of the androgen receptor-controlled proliferation pathway. Chemotherapy only played an additional important role with the advent of taxanes. The progress in translational research in recent years has led to innovations in the therapeutic environment. With the decoding of the homologous repair deficiency (HRD) machinery and its ability to be influenced by PARP inhibitors, targeted therapies moved into the therapeutic focus for selected patients. The first positive phase III study for PARP inhibitors is already available. In addition, immunotherapy for the treatment of prostate cancer, which is now widely used in oncology, is also making progress; both checkpoint inhibitors and bispecific antibodies have shown clinically useful activities. Cellular therapies such as CAR T cells, which are directed against prostate-specific membrane antigen (PSMA), are still at an early stage of development. In this review, the authors provide a summary of the basic principles and clinical development of these new therapies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Guellrich, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Noessner, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gruenwald, V UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-336890
DOI:	10.1007/s00120-020-01198-6
Journal or Publication Title:	Urologe
Volume:	59
Number:	6
Page Range:	S. 687 - 695
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0563
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROFOUND PHASE-III; T-CELLS; OLAPARIB; TRIAL; ENZALUTAMIDE; MULTICENTER; IPILIMUMAB; CHECKPOINT; LYMPHOMA; DEFECTS Multiple languages Urology & Nephrology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/33689